Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening
Acta Pharmaceutica Sinica B
; (6): 222-236, 2021.
Article
de En
| WPRIM
| ID: wpr-881092
Bibliothèque responsable:
WPRO
ABSTRACT
Lianhuaqingwen (LHQW) capsule, a herb medicine product, has been clinically proved to be effective in coronavirus disease 2019 (COVID-19) pneumonia treatment. However, human exposure to LHQW components and their pharmacological effects remain largely unknown. Hence, this study aimed to determine human exposure to LHQW components and their anti-COVID-19 pharmacological activities. Analysis of LHQW component profiles in human plasma and urine after repeated therapeutic dosing was conducted using a combination of HRMS and an untargeted data-mining approach, leading to detection of 132 LHQW prototype and metabolite components, which were absorbed
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Diagnostic_studies
/
Screening_studies
langue:
En
Texte intégral:
Acta Pharmaceutica Sinica B
Année:
2021
Type:
Article